Oncocyte Corporation Common Sto (OCX) 4.12 $OCX
Post# of 273254
Posted On: 09/20/2016 11:06:40 AM
Oncocyte Corporation Common Sto (OCX) 4.12 $OCX
OncoCyte Corporation to Present at the 2016 Aegis Growth Conference
GlobeNewswire - Tue Sep 20, 5:30AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the 2016 Aegis Growth Conference on Thursday, September 22, 2016 at 5:30 p.m. ET/ 2:30 p.m. PT. The conference will be held at the Encore at Wynn Hotel in Las Vegas.
OCX: 4.12 (+0.19)
OncoCyte to Present Initial Data on its Breast Cancer Diagnostic Test at the Prestigious San Antonio Breast Cancer Symposium
GlobeNewswire - Thu Sep 08, 5:00AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that its breast cancer abstract has been selected for presentation in a poster session, at the 2016 San Antonio Breast Cancer Symposium (SABCS) in December at the Henry B. Gonzalez Convention Center in San Antonio, TX.
OCX: 4.12 (+0.19)
OncoCyte Corporation to Present at the Annual Gateway Conference
GlobeNewswire - Wed Sep 07, 5:30AM CDT
OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the Annual Gateway Conference on Thursday, September 8, 2016 at 3:30 p.m. ET / 12:30 p.m. PT. The conference will be held at the Four Seasons Hotel in San Francisco.
OCX: 4.12 (+0.19)
Don M. Bailey Appointed to OncoCyte Corporation's Board of Directors
GlobeNewswire - Mon Aug 29, 3:15PM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood and urine based tests for the early detection of cancer, today announced the appointment of Don M. Bailey to the Company's Board of Directors. Mr. Bailey will also be making a $750,000 investment in OncoCyte as part of the financing announced today by the Company.
OCX: 4.12 (+0.19), AST: 4.47 (+0.05)
OncoCyte Corporation Announces the Closing of Two Private Placement Transactions Generating Gross Proceeds of $10.55 Million
GlobeNewswire - Mon Aug 29, 3:05PM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it has closed two separate private placements with a select group of institutional and accredited investors, including both new and existing investors. The private placements in total will consist of 3,246,153 units for total gross proceeds of $10.55 million before deducting placement agent fees and offering expenses.
OCX: 4.12 (+0.19)
OncoCyte Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 3:01PM CDT
OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, today reported its financial results for the second quarter ended June 30, 2016 along with an update on recent corporate developments.
OCX: 4.12 (+0.19)
OncoCyte Commences Analytical Verification Study for Lung Cancer Diagnostic Test
GlobeNewswire - Wed Aug 10, 5:30AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, today announced that it has initiated the analytical verification study for its lung cancer diagnostic test. The verification study is a first step in the process to independently replicate the positive research results from a 610 patient study by The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, which was announced in April. The OncoCyte study has commenced with the analysis of the first 100 malignant and benign lung cancer samples independently collected by OncoCyte. The Company expects to complete its studies later this year and if the findings are consistent with the earlier Wistar results, it plans to apply to the State of California for CLIA certification of its laboratory and launch its lung cancer diagnostic test in the U.S. during the first half of 2017.
OCX: 4.12 (+0.19)
BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
BusinessWire - Tue Aug 09, 3:18PM CDT
--Deconsolidation Simplifies Financials
OCX: 4.12 (+0.19), BTX: 3.48 (+0.08), AST: 4.47 (+0.05)
OncoCyte Presents Positive Bladder Cancer Diagnostic Data at the 2016 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Mon Jun 06, 5:30AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, is presenting data today from a bladder cancer study featured as a poster and also highlighted during a live panel discussion during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
OCX: 4.12 (+0.19)
OncoCyte to Release Bladder Cancer Data at the 2016 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu May 19, 8:46AM CDT
OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive tests for the early detection of cancer, released today the abstract of data from a bladder cancer study that will be presented as a poster and also highlighted during a live panel discussion on June 6, 2016, during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Illinois.
OCX: 4.12 (+0.19)
OncoCyte Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 18, 3:05PM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, today reported its financial results for the quarter ended March 31, 2016 along with an update on recent corporate developments.
OCX: 4.12 (+0.19)
OncoCyte to Report First Quarter Financial Results on May 18, 2016
GlobeNewswire - Thu May 12, 6:00AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended March 31, 2016 on Wednesday, May 18, 2016 after the close of the U.S. financial markets . The Company will host a conference call on Wednesday, May 18, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results along with recent corporate developments.
OCX: 4.12 (+0.19)
OncoCyte's Bladder Cancer Abstract to be Featured in a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu Apr 21, 5:30AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that its bladder cancer abstract has been selected for presentation in a poster session, including a live panel discussion on the results, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Illinois June 3 through the 7.
OCX: 4.12 (+0.19)
OncoCyte Corporation to Present at the 2016 BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at The 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 8:30 a.m. ET. The conference will be held in New York, NY.
OCX: 4.12 (+0.19)
OncoCyte Corporation and The Wistar Institute Enter Into Global Licensing Agreement
GlobeNewswire - Wed Jan 27, 6:02AM CST
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, and The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, have entered into a definitive global licensing agreement for a simple, non-invasive, blood test to aid physicians in the early detection of lung cancer. The agreement provides OncoCyte the exclusive rights to commercialize this lung cancer diagnostic test.
OCX: 4.12 (+0.19)
Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018
BusinessWire - Tue Jan 12, 4:27PM CST
BioTime, Inc. (NYSE MKT and TASE: BTX) announced today that pursuant to Section 6.1(c) of the Warrant Agreement dated as of October 1, 2013, as amended September 19, 2014, between BioTime and American Stock Transfer & Trust Company LLC as Warrant Agent (the "Warrant Agreement"
governing the BioTime Common Share Purchase Warrants Expiring October 1, 2018 (the "Warrants", the Board of Directors of BioTime adjusted the number of BioTime common shares ("Warrant Shares" that may be purchased upon the exercise of each Warrant, and the purchase price payable for each Warrant Share (the "Warrant Price", as a result of BioTime's distribution of 4,744,707 shares of common stock, no par value, of BioTime's subsidiary OncoCyte Corporation ("OncoCyte" to BioTime shareholders on December 31, 2015 (the "Distribution".
OCX: 4.12 (+0.19), BTX: 3.48 (+0.08)
OncoCyte Corporation to Present at the 2016 Aegis Growth Conference
GlobeNewswire - Tue Sep 20, 5:30AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the 2016 Aegis Growth Conference on Thursday, September 22, 2016 at 5:30 p.m. ET/ 2:30 p.m. PT. The conference will be held at the Encore at Wynn Hotel in Las Vegas.
OCX: 4.12 (+0.19)
OncoCyte to Present Initial Data on its Breast Cancer Diagnostic Test at the Prestigious San Antonio Breast Cancer Symposium
GlobeNewswire - Thu Sep 08, 5:00AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that its breast cancer abstract has been selected for presentation in a poster session, at the 2016 San Antonio Breast Cancer Symposium (SABCS) in December at the Henry B. Gonzalez Convention Center in San Antonio, TX.
OCX: 4.12 (+0.19)
OncoCyte Corporation to Present at the Annual Gateway Conference
GlobeNewswire - Wed Sep 07, 5:30AM CDT
OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the Annual Gateway Conference on Thursday, September 8, 2016 at 3:30 p.m. ET / 12:30 p.m. PT. The conference will be held at the Four Seasons Hotel in San Francisco.
OCX: 4.12 (+0.19)
Don M. Bailey Appointed to OncoCyte Corporation's Board of Directors
GlobeNewswire - Mon Aug 29, 3:15PM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood and urine based tests for the early detection of cancer, today announced the appointment of Don M. Bailey to the Company's Board of Directors. Mr. Bailey will also be making a $750,000 investment in OncoCyte as part of the financing announced today by the Company.
OCX: 4.12 (+0.19), AST: 4.47 (+0.05)
OncoCyte Corporation Announces the Closing of Two Private Placement Transactions Generating Gross Proceeds of $10.55 Million
GlobeNewswire - Mon Aug 29, 3:05PM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it has closed two separate private placements with a select group of institutional and accredited investors, including both new and existing investors. The private placements in total will consist of 3,246,153 units for total gross proceeds of $10.55 million before deducting placement agent fees and offering expenses.
OCX: 4.12 (+0.19)
OncoCyte Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 3:01PM CDT
OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, today reported its financial results for the second quarter ended June 30, 2016 along with an update on recent corporate developments.
OCX: 4.12 (+0.19)
OncoCyte Commences Analytical Verification Study for Lung Cancer Diagnostic Test
GlobeNewswire - Wed Aug 10, 5:30AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, today announced that it has initiated the analytical verification study for its lung cancer diagnostic test. The verification study is a first step in the process to independently replicate the positive research results from a 610 patient study by The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, which was announced in April. The OncoCyte study has commenced with the analysis of the first 100 malignant and benign lung cancer samples independently collected by OncoCyte. The Company expects to complete its studies later this year and if the findings are consistent with the earlier Wistar results, it plans to apply to the State of California for CLIA certification of its laboratory and launch its lung cancer diagnostic test in the U.S. during the first half of 2017.
OCX: 4.12 (+0.19)
BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
BusinessWire - Tue Aug 09, 3:18PM CDT
--Deconsolidation Simplifies Financials
OCX: 4.12 (+0.19), BTX: 3.48 (+0.08), AST: 4.47 (+0.05)
OncoCyte Presents Positive Bladder Cancer Diagnostic Data at the 2016 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Mon Jun 06, 5:30AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, is presenting data today from a bladder cancer study featured as a poster and also highlighted during a live panel discussion during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
OCX: 4.12 (+0.19)
OncoCyte to Release Bladder Cancer Data at the 2016 American Society of Clinical Oncology Annual Meeting
GlobeNewswire - Thu May 19, 8:46AM CDT
OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive tests for the early detection of cancer, released today the abstract of data from a bladder cancer study that will be presented as a poster and also highlighted during a live panel discussion on June 6, 2016, during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Illinois.
OCX: 4.12 (+0.19)
OncoCyte Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 18, 3:05PM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, today reported its financial results for the quarter ended March 31, 2016 along with an update on recent corporate developments.
OCX: 4.12 (+0.19)
OncoCyte to Report First Quarter Financial Results on May 18, 2016
GlobeNewswire - Thu May 12, 6:00AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended March 31, 2016 on Wednesday, May 18, 2016 after the close of the U.S. financial markets . The Company will host a conference call on Wednesday, May 18, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results along with recent corporate developments.
OCX: 4.12 (+0.19)
OncoCyte's Bladder Cancer Abstract to be Featured in a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu Apr 21, 5:30AM CDT
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that its bladder cancer abstract has been selected for presentation in a poster session, including a live panel discussion on the results, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Illinois June 3 through the 7.
OCX: 4.12 (+0.19)
OncoCyte Corporation to Present at the 2016 BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at The 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 8:30 a.m. ET. The conference will be held in New York, NY.
OCX: 4.12 (+0.19)
OncoCyte Corporation and The Wistar Institute Enter Into Global Licensing Agreement
GlobeNewswire - Wed Jan 27, 6:02AM CST
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, and The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, have entered into a definitive global licensing agreement for a simple, non-invasive, blood test to aid physicians in the early detection of lung cancer. The agreement provides OncoCyte the exclusive rights to commercialize this lung cancer diagnostic test.
OCX: 4.12 (+0.19)
Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018
BusinessWire - Tue Jan 12, 4:27PM CST
BioTime, Inc. (NYSE MKT and TASE: BTX) announced today that pursuant to Section 6.1(c) of the Warrant Agreement dated as of October 1, 2013, as amended September 19, 2014, between BioTime and American Stock Transfer & Trust Company LLC as Warrant Agent (the "Warrant Agreement"
governing the BioTime Common Share Purchase Warrants Expiring October 1, 2018 (the "Warrants", the Board of Directors of BioTime adjusted the number of BioTime common shares ("Warrant Shares" that may be purchased upon the exercise of each Warrant, and the purchase price payable for each Warrant Share (the "Warrant Price", as a result of BioTime's distribution of 4,744,707 shares of common stock, no par value, of BioTime's subsidiary OncoCyte Corporation ("OncoCyte" to BioTime shareholders on December 31, 2015 (the "Distribution". OCX: 4.12 (+0.19), BTX: 3.48 (+0.08)
(0)
(0)Scroll down for more posts ▼